FDA begins move to unveil secret data

For years the FDA has kept a mother lode of data on drugs and devices under wraps, careful to protect developers' trade secrets. But new leadership at the FDA wants to open some of that data to public scrutiny to help satisfy critics unhappy about the agency's uneven record on drug safety. A more open approach to data would save lives, they say. But biopharma companies will be watching closely to make sure they aren't damaged in the move toward greater transparency. Report 

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.